Steven Deeks: Pioneering HIV Research
Ever since Steven Deeks began treating HIV and AIDS patients at San Francisco General Hospital in 1993, he became deeply engaged with the community, particularly those with atypical illness trajectories. Curious about why some patients deteriorated more slowly, Deeks pondered the differences in their viruses or immune systems.
Decades later, Deeks stands as a leading researcher at Ward 86, a prominent AIDS clinic. The number of deaths from AIDS has surpassed 40 million, even while treatment has evolved. Combination antiretroviral therapy has transformed HIV from a fatal illness into a manageable chronic disease.
Despite advancements, antiretroviral drugs only suppress HIV; they don’t eliminate it. This raises an enduring question: Can the immune system be trained to control HIV independently? Recent findings suggest it can.
Recent Findings
In a 2020 study, ten HIV-positive individuals engaged in an intensive program designed by Deeks, receiving treatments aimed at enhancing their immune responses. Subsequent analysis revealed that seven out of ten managed to control the virus without ongoing antiretroviral treatments. Remarkably, in one case, HIV remained undetectable for over 18 months.
Follow-up analyses indicated early signs of immune mobilization before the virus became detectable again, hinting at how the treatment may have primed the participants’ immune systems. Although the study’s sample size was small and lacked controls, the results represent significant progress in understanding HIV control.
Deeks expressed optimism, stating, “For the first time ever, we are showing that we can reshape the immune response to HIV for partial control.” The next step is to simplify this treatment to achieve widespread, lasting control of the virus.
Challenges and Funding Concerns
Despite this promising research, challenges remain, particularly as U.S. government funding for HIV research faces cuts. Deeks’s journey underscores both the lengthy process of achieving breakthroughs and the critical need for consistent funding.
From Conventional Thinking to Breakthroughs
Deeks’s unconventional thinking has been crucial. Initially seen as a newcomer, he quickly earned respect for his dedication and intellect. Early lessons, such as the failed baboon bone marrow transplant with activist Jeff Getty, helped shape his trajectory. This experience led him to explore CAR T-cell therapy, where immune cells are engineered to target and attack HIV.
Decades of observation in Ward 86, termed a “living laboratory,” have allowed Deeks to delve into emerging therapies. The transformative introduction of combination antiretroviral drugs in the mid-1990s significantly reduced annual AIDS deaths. Nevertheless, Deeks persisted in seeking ways to teach the immune system to control remaining HIV.
Natural Examples and New Approaches
Insights from rare patients called elite controllers, who naturally manage HIV without treatment, have provided valuable lessons. Notably, Timothy Ray Brown, the first person believed cured of HIV, inspired further research that suggested the persistence of HIV might not be irreversible.
In the recent study involving ten volunteers, Deeks’s team employed various strategies, including therapeutic vaccines and engineered antibodies. Some immune cells showed readiness to respond quickly to HIV reemergence, reminiscent of natural controls observed in elite controllers.
The Way Forward
While promising advances emerge from new studies and treatments, the broader landscape of HIV research faces uncertainties. National Institutes of Health (NIH) funding cuts threaten ongoing projects. The progress made in HIV research has significantly contributed to advancements in cancer treatment and rapid responses to diseases like COVID-19.
Deeks continues to work at Ward 86, engaging with long-term patients and adapting the clinic’s services to their evolving needs. Despite the advances, the fundamental challenge remains: stop treatment, and the virus typically returns.
Now, researchers aim to transform these exceptions into a new standard, paving the way for lasting control over HIV. The journey toward a cure continues, driven by the commitment of those like Deeks dedicated to breaking barriers in HIV treatment and understanding.
